Aytu BioPharma, Inc. cash flow to debt ratio of -8.44% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Aytu BioPharma, Inc.'s free cash flow has decreased 200.82% from $-1.72M last year to $-5.17M, signaling decreasing performance

Aytu BioPharma, Inc.'s debt to equity ratio is 0.65, which means that the company's assets are unhealthy financed, signaling financial risk.

Aytu BioPharma, Inc.'s debt has increased relative to shareholder equity from 0.59 last year to 0.65 today, signaling weakened financials

Aytu BioPharma, Inc. has a net cash position, so leverage is healthy.

Aytu BioPharma, Inc.'s interest coverage ratio is -6.76, which means that the company struggles to meet interest obligations, signaling financial risk.

Aytu BioPharma, Inc.'s profit margin has decreased (147.54%) in the last year from -24.31% to -60.17%, signaling decreasing performance

Aytu BioPharma, Inc.'s short-term assets of $79.18M exceed its short-term liabilities of $63.06M

Aytu BioPharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Aytu BioPharma, Inc.'s return on equity of -148.91%, is lower than 15.00%, indicating bad performance

Aytu BioPharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Aytu BioPharma, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Aytu BioPharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Aytu BioPharma, Inc. has negative free cash flow, indicating cash burn

Aytu BioPharma, Inc.'s yearly earnings has increased -14.40% since last year from $-15.84M to $-13.56M, signaling increasing performance

Aytu BioPharma, Inc.'s yearly revenue has decreased 18.05% since last year from $81.00M to $66.38M, signaling decreasing performance

ROIC -23.62% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Aytu BioPharma, Inc.'s 3-year revenue CAGR of -11.78% is negative, indicating declining revenue over the past 3 years

Aytu BioPharma, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Aytu BioPharma, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Aytu BioPharma, Inc. has insufficient data to evaluate this check.

Aytu BioPharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aytu BioPharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Aytu BioPharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Aytu BioPharma, Inc. is overvalued relative to its fair value price of -32.51 based on Earnings Fair Value model

Aytu BioPharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aytu BioPharma, Inc. has a price-to-book ratio of 0.71x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Aytu BioPharma, Inc. has a price-to-sales ratio of 0.44x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue